In agreement with a previous report35, recombinant human THBS1 reduced CLL cell viability in a time and dose dependent manner after 6 h and 24 h in vitro (Fig. 6g, Supplementary Fig. 4d). This evidence concerns the gene THBS1 and B-cell chronic lymphocytic leukemia.